GALNT14 protein expression was significantly higher in cell lines sensitive to dulanermin and drozitumab compared to that in resistant non–small cell lung cancer (NSCLC) cell lines [41]. The gene discussed is GALNT14; the disease is non-small cell lung carcinoma.